Healthcare Services

Global Neurodiagnostics Market Forecast Highlighting Expansion And Competitive Dynamics

June 2, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Value Of The Neurodiagnostics Market Projected To Expand During 2026–2030?

The neurodiagnostics market has demonstrated robust expansion over recent years. Its valuation is anticipated to rise from $9.79 billion in 2025 to $10.46 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this market’s growth was fueled by an increased prevalence of neurological conditions, the swift adoption of MRI and CT scanning, advancements in EEG and EMG systems, a heightened demand for tools for stroke diagnosis, and the development of neurodiagnostic infrastructure within hospitals.

The neurodiagnostics market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $13.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.5%. This projected growth is driven by several factors, including the proliferation of biomarker-based diagnostics, increased capital expenditure in neuroimaging advancements, the growing acceptance of digital neuroinformatics platforms, the creation of portable and wearable neurodiagnostic tools, and the escalating need for point-of-care neurological examinations. Key trends anticipated during this period encompass the wider utilization of sophisticated neuroimaging techniques, the increased application of in-vitro neurodiagnostic biomarkers, an escalating desire for the prompt identification of neurological conditions, the broadening use of EEG and MEG for continuous brain activity monitoring, and an intensified emphasis on diagnostic methods that are non-invasive or minimally invasive.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20902&type=smp

Which Major Factors Are Contributing To The Development Of The Neurodiagnostics Market?

The rising occurrence of neurological conditions is projected to propel the expansion of the neurodiagnostics market in the coming years. These disorders are defined as ailments affecting the brain, spinal cord, or nerves, resulting in diverse cognitive, motor, and sensory deficits. The surge in neurological conditions primarily stems from an aging global populace, environmental influences, evolving lifestyles, genetic predispositions, and advancements in diagnostic methodologies. Neurodiagnostic tools are crucial for the accurate identification, evaluation, and tracking of neurological disorders, facilitating precise diagnoses, well-informed treatment choices, and efficient handling of ailments impacting the brain, spinal cord, and nerves. As an illustration, information from the National Library of Medicine, a US-based medical research library, indicated in April 2023 that 6.7 million Americans were living with Alzheimer’s in 2023, a figure anticipated to climb to 13.8 million by 2060. Consequently, the growing incidence of neurological conditions is fueling the expansion of the neurodiagnostics market.

How Is Segment Classification Applied In The Neurodiagnostics Market?

The neurodiagnostics market covered in this report is segmented –

1) By Type: Diagnostic And Imaging Solutions, In-Vitro Diagnostics

2) By Technology: Neuroimaging Technologies, Nuclear Medicine Imaging, Near Infrared Spectroscopic Imaging (NIRS), Magneto-Encephalography (MEG), Voxel Based Morphometry (VBM), Neuroinformatics

3) By Condition: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Stroke, Other Conditions

4) By End Use: Hospitals And Clinics, Diagnostic Laboratories, Imaging Centers, Other End Uses

Subsegments:

1) By Diagnostic And Imaging Solutions: MRI (Magnetic Resonance Imaging) Systems, CT (Computed Tomography) Scanners, EEG (Electroencephalogram) Systems, EMG (Electromyography) Systems, MEG (Magnetoencephalography) Systems, PET (Positron Emission Tomography) Scanners, SPECT (Single Photon Emission Computed Tomography) Scanners, Functional MRI (fMRI) Systems, Intracranial Pressure Monitors

2) By In-Vitro Diagnostics: Blood-Based Diagnostics, Cerebrospinal Fluid (Csf) Analysis, Genetic Testing And Biomarkers, Neurochemical Diagnostics, Point-Of-Care Neurodiagnostics, Diagnostic Kits For Neurodegenerative Disorders

Which Trends Are Expected To Shape The Neurodiagnostics Market?

Leading firms within the neurocutaneous disorder market are prioritizing securing regulatory clearances to broaden their range of treatments, improve patient results, and benefit from the increasing need for novel medical solutions. These official permissions from governmental bodies grant a company the legal right to introduce, distribute, or test a medication or treatment, once its safety and efficacy have been established. As an illustration, in September 2025, AstraZeneca plc, a pharmaceutical and biotechnology entity located in the UK, secured the Food and Drug Administration (FDA) approval for selumetinib (brand name Koselugo) for the treatment of pediatric patients aged 1 year and older suffering from neurofibromatosis type 1 (NF1) presenting with symptomatic, inoperable plexiform neurofibromas (PNs). This clearance extends the prior indication, which previously encompassed children aged 2 years and older. Selumetinib, identified as a MEK inhibitor, functions by impeding the MAPK pathway, which drives tumor proliferation in NF1. Patients are administered oral selumetinib twice daily until their condition worsens or intolerable adverse reactions manifest, with typical side effects encompassing gastrointestinal, skin, cardiac, and ocular toxicities. This endorsement provides a vital therapeutic alternative for young children afflicted by these difficult and often disfiguring tumors, which are commonly hard to manage through surgery.

Who Are The Major Companies Operating In The Neurodiagnostics Market?

Major companies operating in the neurodiagnostics market are Nihon Kohden Corporation, Cephalon LLC, Stratus Neuro LLC, Cadwell Industries Inc., Compumedics Limited, Ceribell Inc., CND Life Sciences Inc., Lifelines Neuro Inc., ANT Neuro B.V., Neurovative Diagnostics LLC, Firefly Neuroscience Inc, IntraNerve Neuroscience Inc, NeuroDiagnostics Laboratories LLC, Advanced Brain Monitoring Inc, Spes Medica S.r.l., BioSignal Group Inc, Combinostics Inc., Deymed Diagnostic LLC, NeuLine Health Inc., Ridge Diagnostics Inc., Beacon Biosignals Inc., Intch Inc.

Access The Complete Neurodiagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/neurodiagnostics-global-market-report

Which Region Holds The Largest Share In The Neurodiagnostics Market?

North America was the largest region in the neurodiagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodiagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Neurodiagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20902&type=smp

Browse Through More Reports Similar to the Global Neurodiagnostics Market 2026, By The Business Research Company

Nephrologists Market Global Report 2020 2030 Covid 19 Implications And Growth 2026

https://www.thebusinessresearchcompany.com/report/nephrologists-market-global-report-2020-2030-covid-19-implications-and-growth

Scleroderma Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

Peripheral Neuropathy Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795